Polaryx Strengthens Leadership Ahead of Key Phase 2 Trial — Polaryx Therapeutics, Inc.

Event summary

Polaryx appoints Dr. Will Charlton as Chief Medical Officer, effective September 1, 2026.
Dr. Charlton brings 15+ years of rare disease and pediatric drug development experience.
SOTERIA Phase 2 trial initiation planned for Q4 2026.
Trial will assess PLX-200 in four lysosomal storage disorders (LSDs).
Polaryx received FDA safe-to-proceed letter in October 2025.

The big picture

Polaryx's appointment of Dr. Charlton underscores its focus on strengthening clinical leadership ahead of a critical Phase 2 trial. The move comes as the company prepares to evaluate its lead candidate, PLX-200, in a basket trial targeting four rare pediatric lysosomal storage disorders. The strategic hire highlights the importance of rare disease expertise in navigating complex clinical development pathways, particularly in the competitive landscape of orphan drug therapies.

What we're watching

Trial Execution: Whether Polaryx can efficiently initiate and complete the SOTERIA trial across multiple LSDs.
Regulatory Pathway: The pace at which Polaryx advances PLX-200 toward potential expedited approval.
Leadership Impact: How Dr. Charlton's experience will shape the SOTERIA trial's design and outcomes.